Objective: To retrospectively assess the efficacy and safety of palliative chemoradiotherapy in Stage IVB esophageal cancer patients with dysphagia due to the primary lesion. Methods: Forty patients with dysphagia caused by metastatic esophageal cancer, which had been treated between January 2004 and June 2009, were retrospectively investigated. The treatment consisted of two courses of chemotherapy (5-fluorouracil and cisplatin) and concurrent irradiation of 40 Gy in 20 fractions to the esophageal primary tumor. The grade of dysphagia was evaluated; nutrition-support-free survival was evaluated using the status of nutritional support of patients. Response to treatment, overall survival, progression-free survival and toxicities were also evaluated. Results: Dysphagia score improved in 75% of the patients. Seventeen of the 20 patients (85%) who had required nutritional support at baseline improved their oral intake to no longer need the support, in a median time of 43 days. The median nutrition-support-free survival was 301 days in the 20 patients who had had adequate oral intake before the treatment. Disease control rate of the primary lesion was 95%, including 12 patients (30%) who achieved a complete response. The overall response rate was 55%. The median survival was 308 days, and the 1-year-survival rate was 45.0%. The median progression-free survival was 139 days. Toxicities were generally well tolerated. Major toxicities (Grade 3 or 4) involved hemoglobin (23%), leukocytes (15%), neutrophils (20%), anorexia (10%), nausea (3%), esophageal perforation (5%) and febrile neutropenia (3%). Two patients (5%) died within 30 days of terminating radiotherapy. Conclusions: Palliative chemoradiotherapy using 5-fluorouracil plus cisplatin combined with concurrent 40 Gy irradiation effectively improved the symptom of dysphagia in Stage IVB esophageal cancer with acceptable toxicity and favorable survival.
INTRODUCTION
Esophageal cancer is the sixth most common form of cancer in male and the sixth most common cause of all cancer death. In 2008, estimated 482 600 new cases are diagnosed, and the estimated deaths were 406 800 worldwide (1) . In Japan, 11 669 patients died of esophageal cancer in 2007 (2) . For 8.6% of the patients, the disease has already spread to other organs of the body at the time of diagnosis (3) , and a cure is not expected. Most of these metastatic patients experience dysphagia due to the progression of the primary lesion.
Dysphagia is the most common and serious symptom of esophageal cancer. It severely affects the patient's quality of life and necessitates nutritional support, such as intravenous infusion or feeding through percutaneous gastrostomy or nasogastric tube, when inadequate oral intake persists. For patients with unresectable, metastatic esophageal cancer, long-term relief of dysphagia is one of the most important issues in their daily life (4) .
Of the multiple treatment options for dysphagia, radiotherapy and metallic stent placement have been considered to be the standard of care. When rapid relief of dysphagia is required, stent placement is the preferred treatment; however, its efficacy is short term due to the fact that the tumor masses are only pressed mechanically. Stent deployment in inoperable patients has been reportedly associated with a median survival time of only 13-20 weeks (5-7). For patients in better health, radiotherapy could offer a more prolonged effect (8) .
According to the National Comprehensive Cancer Network (NCCN) clinical practice guidelines in oncology TM v.1.2010, palliative chemotherapy is proposed as the standard treatment in metastatic patients, with the aims of controlling tumor growth, improving quality of life and prolonging survival. Response rates to chemotherapy alone ranged from 16 to 43% for metastatic disease (9 -14) . However, there is little evidence to suggest that chemotherapy alone improves survival and/or quality of life including dysphagia in patients with metastatic disease (9, 15, 16) .
With respect to palliative chemoradiotherapy in patients with further advanced esophageal cancer, including metastatic cases, previous studies have shown considerable effects in the improvement of dysphagia (17 -23) . However, there have been only a few studies covering exclusively Stage IVB esophageal cancer.
The aim of this retrospective study was to provide basic data on the efficacy and toxicity of palliative chemoradiotherapy in Stage IVB esophageal cancer. We especially focused on the improvement of dysphagia, and survival time without nutritional support, because these parameters reflect clinically relevant symptomatic indices in patients suffering from dysphagia due to incurable, metastatic esophageal cancer.
PATIENTS AND METHODS

PATIENTS
The subjects were recruited from our database of patients who were treated at National Cancer Center Hospital East (Kashiwa, Chiba, Japan) between January 2004 and June 2009, according to the following criteria: (i) histologically confirmed squamous cell carcinoma of the esophagus;
(ii) metastatic disease classified as Stage IVB, according to the TNM classification of malignant tumor of UICC, sixth edition; (iii) radiation therapy consisted of 2 Gy fractions (Fr) daily for 20 days (total 40 Gy); (iv) chemotherapy consisted of 5-fluorouracil (5-FU) and cisplatin (CDDP); (v) primary lesion present in thoracic esophagus; (vi) age 20 -75 years; (vii) performance status (PS) 2 on the Eastern Cooperative Oncology Group scale; (viii) no previous history of chemotherapy or radiotherapy; (ix) white blood cell count between 4000 and 20 000/ml; (x) platelet count 100 000/ml or more; (xi) adequate liver function, as indicated by serum concentrations of total bilirubin 2.0 mg/dl, aspartate aminotransferase 200 IU/l and alanine aminotransferase (ALT) 200 IU/l; (xii) serum creatinine concentration 1.5 mg/dl. The metastatic lesions were confirmed with computed tomography scans. The presence of a measurable metastatic lesion was not mandatory. Patients with other active synchronous carcinomas or concurrent uncontrolled medical illness were excluded. The study was performed in accordance with the Declaration of Helsinki and Japanese ethical guidelines for epidemiological research. We obtained an institutional review board (IRB) waiver to conduct this study from the chairperson of the IRB.
TREATMENT SCHEDULE
Chemotherapy comprised protracted infusion of 5-FU combined with a 2 h infusion of CDDP with adequate hydration and antiemetic coverage. In general, patients were treated with 5-FU 700 mg/m 2 on days 1 -4 and 29 -32, and CDDP 70 mg/m 2 on days 1 and 29 ( Fig. 1 ). Doses were modified according to the judgment of the attending physician: the doses of 5-FU and CDDP were generally reduced to 50 -80% when Grade 4 hematological or Grade 3 or 4 non-hematological toxicity occurred. Once serious toxicity was observed, treatment was suspended until recovery.
Radiation treatment (10 MV) was administered for 4 weeks (5 days/week) at 2 Gy/day with a total radiation dose of 40 Gy/20 Fr, concomitantly with chemotherapy ( Fig. 1) . The chemotherapy and radiotherapy were started within 7 days of each other. The targeted area for irradiation included only the primary tumor with a 3 cm superior and inferior margin and a 2 cm lateral margin. Metastatic lesions were not included in the targeted area. Irradiation was applied in anterior and posterior opposed fields.
When there was a need, nutritional support was provided by fluid administration including intravenous hyperalimentation or feeding through a percutaneous gastrostomy tube. Jpn J Clin Oncol 2011;41 (8) 965
For patients who showed an objective response to treatment, additional courses of chemotherapy alone were administered, which consisted of the same regimen or protracted infusional 5-FU 800 mg/m 2 /day on days 1 -5 and a 2 h infusion of CDDP 80 mg/m 2 /day on day 1. These treatments were repeated every 4 weeks until disease progression, development of unacceptable toxicity or the patient's refusal to continue. Further additional courses of chemotherapy were optional. When disease progression or unacceptable toxicities were observed, second-line chemotherapy was initiated.
RESPONSE AND TOXICITY EVALUATION
The grade of dysphagia was determined by the dysphagia score as described previously and shown in Table 1 (24, 25) . Improvement of dysphagia was defined as a decrease of at least 1 point in dysphagia score.
Objective responses of measurable metastatic lesions were evaluated according to the response evaluation criteria in solid tumors (RECIST v 1.0) guideline. Tumor response was evaluated using computed tomography scan every 8 weeks after the initiation of treatment. Response of the primary tumor was evaluated by the criteria of the Japan Esophageal Society (26, 27) . Complete response (CR) of the primary lesion is judged, using endoscopy, with the fulfillment of all of the following conditions: (i) disappearance of all endoscopic findings that suggest the presence of tumor, such as irregular erosive lesions, ulcerative lesions or obvious elevated lesions; (ii) no histologic findings of malignant cells by endoscopic biopsy from the area where the primary tumor had been; (iii) the entire esophagus can be observed by endoscopy; and (iv) no findings of active esophagitis by endoscopy. Progressive disease (PD) of the primary lesion means distinct tumor growth or progression in esophageal stenosis during treatment. Incomplete response/stable disease (IR/SD) means that the response of the primary lesion does not meet the conditions for CR or PD.
Toxicity was evaluated according to the Common Terminology Criteria for Adverse Events v3.0 (CTCAE v3.0). Toxicity was assessed on a weekly basis during chemoradiotherapy and then biweekly during the subsequent chemotherapy.
STATISTICAL ANALYSIS
Overall survival was calculated from the initiation of treatment to the date of death or the last follow-up day in survivors. Progression-free survival was calculated from the initiation of treatment to the detection of disease progression or death from any cause. In patients who had not required (Fig. 2) .
Of the 143 patients treated with chemoradiotherapy, 50 were treated with the palliative regimen of chemotherapy with 5-FU and CDDP and 40 Gy/20 Fr of irradiation to exclusively the primary lesion. Of these 50 patients, 10 were excluded from our study: 3 were older than 75 years; 1 had basal cell carcinoma; 3 had a primary lesion located in the cervical esophagus; 1 did not experience dysphagia; 1 had advanced gastric cancer; and 1 developed a severe infection immediately before treatment started. The remaining 93 patients had been treated with other regimens, such as 5-FU and CDDP combined with 50.4 or 60 Gy irradiation, or 5-FU plus nedaplatin with radiation.
The characteristics of the 40 eligible patients are shown in Table 2 . Most of the patients (95%) had good PS of 0 or 1.
COMPLIANCE AND EFFICACY
All patients completed the planned radiotherapy. Radiation schedule was interrupted for 1 day or more in seven cases (18%) because of infection or high fever (Grade 1 or 2), but all completed the program after an intermission.
The median number of courses in the initial regimen of chemotherapy was four, ranging from one to seven courses. Treatment discontinuation within two courses was observed in two patients. The regimen was changed to 5-FU and nedaplatin in one patient at the physician's discretion. Chemotherapy was terminated in the other patient because of disease progression after the first course of chemotherapy. In seven patients, the dose was reduced (to 50 -80%) for the second course because of toxicities observed in the first course.
The responses of the primary lesions are shown in Table 3 : 12 patients (30%) achieved a CR in their primary lesion and 26 (65%) were categorized as having IR/SD. Of these patients, 24 demonstrated apparent regression of the primary lesion, which means that 90% of the patients showed volume reduction in the primary lesion after chemoradiotherapy. As for the overall response including metastatic lesions, objective improvement was seen in 22 patients, a 55% response rate (Table 4) .
EVALUATION OF DYSPHAGIA AND SURVIVAL
All patients were assessable for degree of dysphagia, history of oral intake, toxicity, overall survival and progression-free Jpn J Clin Oncol 2011;41 (8) 967 survival. Nutrition-support-free survival could also be assessed in all patients. Twenty patients who had received nutritional support of total parenteral nutrition or percutaneous gastrostomy at the onset of treatment were assessable for improvement in oral intake. The overall improvement rate of dysphagia score was 75% (30/40) ( Table 5 ). The nutrition-support-free survival of the 20 patients with initially adequate oral intake is shown in Fig. 3 . The median nutrition-support-free survival was 301 days (10.0 months). The median overall survival in this group of patients was 410 days (13.7 months). Of the other 20 patients who had initially required nutritional support, 85% (17/20) were relieved from nutritional support: median overall survival was 249 days (8.3 months). Of the 17 patients who were relieved from nutritional support, the median time until relief of nutritional support was 43 days (1.4 months) and the median nutrition-support-free duration was 137 days (4.6 months).
The median follow-up period was 617 days in survivors at the time of analysis. The overall survival time is shown in Fig. 4 . The median survival time was 308 days (10.3 months), and the 1-year-survival rate was 45.0%. The median progression-free survival was 139 days (4.6 months) (Fig. 5) .
TOXICITY
The grades of toxicity during the treatment course (radiotherapy and first and second course of chemotherapy) are summarized in Table 6 . Toxicity profiles with Grade 3 and 4 are shown except for platelet. Hematological toxicities were generally mild. Anemia was the most common hematological toxicity, but only 23% of the patients experienced Grade 3 or 4 anemia. Grade 3 or 4 neutropenia and leukopenia occurred in 15 and 20% of the patients, respectively. Grade 3 or 4 non-hematological toxicities were hyponatremia (18%), anorexia (10%), nausea (3%), esophageal perforation (5%), ALT (5%), creatinine (3%), febrile neutropenia (3%), rash (3%) and constipation (3%).
No patient died during radiotherapy. However, early death, within 30 days of terminating radiotherapy, occurred 
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Palliative chemoradiotherapy for Stage IVB esophageal cancer in two patients: one was a 64-year-old man who had supraclavicular lymph node metastases. The primary tumor had not invaded adjacent organs (T3), but one metastatic lymph node had invaded the wall of the aorta. On the 13th day after terminating radiotherapy, the patient was admitted to the hospital as an emergency due to severe right pneumonia; he died the next day. Chest X-ray indicated pneumonia due to aspiration or perforation, so the probability of radiation pneumonitis was low. The other patient was a 71-year-old man who had deep cervical and supraclavicular lymph node metastases and pericardial dissemination. The primary tumor invaded the wall of the aorta, bronchus and pericardium (T4). On the 26th day after terminating radiotherapy, the patient complained of severe back pain. After a few hours, he was found in cardiac arrest. The causes of death in these two cases are not clear, but they could be related to treatment.
DISCUSSION
Palliative chemoradiotherapy using 5-FU plus CDDP combined with concurrent 40 Gy irradiation effectively improved the symptom of dysphagia in Stage IVB esophageal cancer with acceptable toxicity and favorable survival in our study.
To date, the best palliative method for dysphagia due to advanced esophageal cancer has not been established. Of the multiple treatment options, chemoradiotherapy had been reported to be effective for the palliation of dysphagia through tumor regression in advanced, incurable esophageal cancer (17 -23) . However, these previous studies included patients who were not uniform in terms of TNM clinical classification. In palliative chemoradiotherapy for patients with Stage IVB esophageal cancer accompanied by dysphagia, it is most important to balance management of primary and metastatic sites with tolerance of toxicity. Therefore, to prolong survival without nutritional support, it is important to establish the appropriate dose of individual agents and irradiation dose and field. Our study is one of only a few to investigate the palliative effects of chemoradiotherapy exclusively in patients with Stage IVB esophageal cancer.
In our study, the palliative chemoradiotherapy was satisfactory, with an overall improvement rate in dysphagia score as high as 75%. Of the patients who had required nutritional support at the onset of treatment, 85% no longer needed the support after the treatment. The toxicity was tolerable, and the median overall survival was 10.3 months in patients with Stage IVB esophageal cancer accompanied by dysphagia. We suggest that concurrent chemoradiotherapy of 5-FU plus CDDP combined with 40 Gy irradiation is effective in improving dysphagia.
Published reports of palliative chemoradiotherapy are summarized in Table 7 (17,18,20 -23) . The chemotherapy regimens in these studies are basically a combination of 5-FU and another agent, and the radiation dose ranges between 30 and 54 Gy, which is generally lower than the dose used in definitive chemoradiotherapy. Our regimen, chemotherapy with 5-FU and CDDP, and concurrent radiation of 40 Gy, can be properly categorized in the spectrum of palliative therapy. Hayter et al. (18) showed in detail the palliative efficacy of 30 Gy radiation in 10 Fr with concurrent chemotherapy consisting of 5-FU and mitomycin C in 22 patients with advanced incurable esophageal cancer. In that study, complete relief of dysphagia was observed in 68% of the patients. The median time to normalization of swallowing was 5 weeks, and the median dysphagia-free interval from the onset of improvement was 11 weeks. In the other reports, the improvement rate of dysphagia ranged from 67 to 91% (Table 7 ). The effects of our palliative regimen are comparable to those reported in these studies. Our treatment regimen was well tolerated. No patient failed to complete radiation, and only two patients (5%) received fewer than two complete courses of the planned chemotherapy. Death within 30 days of completion of radiation was observed in two patients (5%). The rates of treatment failure and treatment-related deaths in the previous studies are shown in Table 7 . As for these two parameters, the toxicity profile of our regimen is equivalent to those of the previous studies.
There have been some studies evaluating chemotherapy for locally advanced or metastatic squamous cell esophageal cancer (10 -14) . Bleiberg et al. (12) reported that WHO Grade 3 and 4 toxicities were observed from combined chemotherapy of 5-FU and CDDP: leukocytes in 14% of the patients and platelets in 14%. Iizuka et al. (14) evaluated the combination of 5-FU and CDDP in advanced squamous cell carcinoma of the esophagus and reported WHO Grade 3 and 4 toxicities of hemoglobin, leukocytes and platelets in 13, 8 and 5% of the patients, respectively. In our study, CTCAE Grade 3 and 4 leukocytes, hemoglobin and platelets developed in 15, 23 and 0% of the patients, respectively. The higher rates of hematological toxicities in our study seem to arise because of the concurrent radiation. In the studies of definitive chemoradiotherapy with a radiation dose of 50 -70 Gy (20,28 -32) , Grade 3 and 4 toxicities were observed at a rate of 9 -33% hemoglobin, 24 -78% leukocytes and 14 -20% platelets. These figures are generally higher than in our study, probably due to the higher radiation dose. Non-hematological toxicities were not severe in our study. Although Grade 3 esophageal perforation and febrile neutropenia occurred in 5 and 3% of the patients, respectively, they were properly managed.
Regression of the primary lesion was observed in 90% of the patients and 12 (30%) achieved CR. This effect probably results in the effective improvement of dysphagia. In definitive chemoradiotherapy of esophageal cancer, the irradiation dose to the primary lesion is 50.4 or 60 Gy in Japan. The CR rates of the primary lesion following definitive chemoradiotherapy are 62% in T3 cases and 37% in T4 cases, respectively (33) . The CR rate of the primary lesion in our study was lower than this, probably because of the lower radiation dose of 40 Gy. A higher dose could lead to better and longer dysphagia relief through tumor regression, but it is important to balance palliative outcome with the costs of treatment, namely toxicities of higher irradiance and the effort of hospital visits, especially in those patients who cannot expect a cure.
The prognosis of Stage IVB esophageal cancer is poor. The median survival time has been reported to be 5 -11 months (7, 11, 17, 18, 22, 23, 29, 34) in patients who receive any treatment (including chemotherapy, chemoradiotherapy or surgery). In our study, the median survival time was 10.3 months, which is relatively good compared with previous studies of palliative therapies including chemoradiotherapy ( Table 7 ). The survival effect is an important therapeutic aim in incurable Stage IVB esophageal cancer. Our result suggests that the addition of 40 Gy of radiotherapy to palliative chemotherapy is not associated with a negative effect on survival. However, we have to accept that there could be a selection bias in our retrospective study. It should be noted that 24 out of 40 patients have only lymph node metastasis in our study, who are known to have better outcome than those with visceral metastasis.
As for the histological type of the tumor, both squamous cell carcinoma and adenocarcinoma were included in the western studies (17) (18) (19) (20) 23) , whereas only squamous cell carcinoma was included in Asian studies, including ours (21). The incidence of adenocarcinoma of the esophagus has increased considerably in western countries over the past three decades (35) , whereas squamous cell carcinoma remains the major histological type of esophageal cancer in Japan and most Asian countries. It has been reported that there has been no dramatic increase in adenocarcinoma in Japan (36). Our study included only patients with squamous 
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Palliative chemoradiotherapy for Stage IVB esophageal cancer cell carcinoma, in order that we represent actual Japanese clinical practice.
In conclusion, our retrospective study suggests that our palliative regimen of chemoradiotherapy, 5-FU plus CDDP combined with concurrent 40 Gy irradiation, can provide effective palliation of dysphagia through tumor regression with a tolerable toxicity profile in incurable Stage IVB esophageal cancer. However, since there are inevitable biases that could not be ruled out in our retrospective study, further prospective studies are required to elucidate the most durable and swift palliation with lower toxicity and better survival.
